Wells Fargo analyst Yanan Zhu maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) yesterday and set a price target of ...

ADAP Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptimmune Therapeutics (ADAP – Research ...

Adaptimmune (NASDAQ:ADAP) is scheduled to announce Q4 earnings results on Thursday, March 20th, before market open. The consensus EPS Estimate is -$0.15 (-275.0% Y/Y) and the consensus Revenue ...

Every investor in Adaptimmune Therapeutics plc (NASDAQ:ADAP) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 50% ...

Short interest in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) increased during the last reporting period, rising from 5.76M to 6.88M. This put 4.03% of the company's publicly available shares short.

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...